Podcasts about google play store

The TKI Crew are back asking the age old question, "Do you have to go a Division 1 school as a goalkeeper to play at the next level? The gang breaks down all the pluses and minuses of focusing solely on D1 opps and why environment matters more than level. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Grundsätzlich sind Doktorspiele ganz normale “Zeig mal, guck mal” -Spiele und wir alle wissen, dass sie irgendwie dazu gehören. Aber wie sollen wir Eltern uns verhalten? Und woran merken wir, wenn es nicht mehr harmlos ist?  In dieser Podcastfolge gibt Nicola einen Überblick, in welchem Alter Doktorspiele normal sind, woran wir erkennen, was unsere Kinder gerade spielen und welche Informationen alle Kinder brauchen.  Mehr bekommst du in unserer App »artgerecht - für Eltern (Selbstfürsorge • Erziehungstipps)« in deinem App Store oder Google Playstore.

With the midweek win done and dusted, we can finally focus on the meat and potatoes of the MLS regular season! Just two months away from competition feels like a hunger strike, especially after watching That Team From Florida enjoy all the fine dining last December. FC Cincinnati heads into Season 5 under Pat Noonan with some big statements to make, but let's not forget that this weekend's opponent experienced bigger disappointment after promises of gold. Atlanta United brought the band back together by rehiring their best conductor, Tata Martino, to helm the sidelines. What can we expect out of the "5 Stripes" with a similar roster and a more familiar head coach? We've brought in an old friend to the show, Tyler Pilgrim from Scarves & Spikes, to set the table for Saturday. Can Atlanta bring back the golden days of the 2010s and get back on the medal stand again? What will the Starting XI look like under Martino's guidance? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

This week, we're revisiting an episode where Marianna sat down with John Faragon to talk about post-exposure prophylaxis in pocket or PIP. Listen in to learn all about what it is, who it's for, and how it can help prevent HIV for more people.-- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

In Episode 56 Landon urges us to slow down a bit, to relax. One of the ways in which we accomplish this is to Embrace Life's Undeniables. This is the 4th Key to living fully...excerpted from "The Significant Seven", a 7-part addition to the Heartbeat App. You can get the entire course, including thought provoking insights from Landon and an accompanying exploration workbook, now included in the Heartbeat App. The App is free, and can be downloaded from the Apple App Store or the Google Play Store.

The TKI Crew keeps it rolling with a "Brave" Pod :P. That's right, today's topic is what it means to be a brave goalkeeper. The crew breaks it down from a micro and macro standpoint.  Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I18 GK Podcast is back this month w/ Sac Republic's Kris Hall! The crew chat overseas badges, the upcoming USSF course, and how to balance your independent academy w/ your Pro Club's commitments. Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code: Union GK members can save an additional 10% with code: UGK23. Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment. Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Want to increase your organic downloads without spending money on ads? In this video, I break down our proven app store optimization (ASO) framework for 2026. Whether you are an indie developer or managing a big brand, these strategies will help you rank higher on both the Apple App Store and Google Play Store.We cover the exact steps we use at App Masters to help clients find success, from keyword research to conversion rate optimization.In this ASO tutorial, you will learn:✅ The most important ASO ranking factors in 2026✅ How to find low-competition keywords that still drive revenue✅ The do's and dont's of selecting keywords✅ Some Real Case Studies:- $1,600 in revenue in the first 22 days from organic search- $3,000/month purely from long-tail ASO strategy- 90+ #1 keyword rankings using low-traffic terms

It's that time of year again as the Geek Salad crew waxes nostalgic about the music from 30 years ago. In this installment, they discuss their favorite album releases of the year 1996! Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

At ITEXPO / MSP EXPO in Fort Lauderdale, Doug Green, Publisher of Technology Reseller News, spoke with Jon Brinton, Chief Revenue Officer at Crexendo, about the company's latest announcement: the launch of the Crexendo Marketplace. Crexendo is also a member of the Cloud Communications Alliance (CCA). Crexendo, a unified communications service provider, merged with NetSapiens five years ago, bringing together a robust UCaaS platform now powering approximately 240 service providers globally. That ecosystem supports nearly 7.5 million users—a number that has grown more than fourfold since the acquisition. The new Crexendo Marketplace builds on that momentum by delivering a centralized, frictionless application store for certified integrations and third-party solutions. “What we've now released is a Crexendo Marketplace,” Brinton explained. “If you think about it like the Google Play Store or the Apple Store, it's an application store that somebody can go to download, activate or integrate with applications that are certified for our platform.” Through one-touch provisioning, service providers can enable integrations such as mobile dialer support, analytics, Microsoft Teams connectivity, and Crexendo's AI-powered receptionist and orchestrator, Cairo—all without complex implementation paths. The Marketplace reinforces Crexendo's sessions-not-seats licensing model, which allows MSPs and service providers to own their customer relationships while building equity in their businesses. Brinton noted that AI-driven add-on applications are driving significant incremental revenue, often far exceeding traditional per-user UCaaS pricing. “Some of these AI applications… may be worth four to five to ten times that in monthly revenue to our partners,” he said, underscoring the opportunity for higher-margin growth. As innovation accelerates across the cloud communications landscape, Crexendo continues to invest heavily in platform development and ecosystem expansion. With its annual NetSapiens user group meeting scheduled for Austin later this year, the company remains focused on empowering partners with tools, integrations, and community support to compete—and win—in an evolving market. Visit https://www.crexendo.com/

One week until meaningful soccer and the launch of a promising FC Cincinnati season! We enter Year 11 the same way as last season, with the Orange & Blue leaving the country for CONCACAF Champions Cup coverage. Soon enough, the MLS season also starts with designated players Evander, Miles Robinson, and Kevin Denkey leading a talented roster. But what are we really looking at? How promising and hopeful are we that this roster can use consistency and build from last season's hard work? We ask the FC Cincinnati radio broadcast team, Tommy G. and Kevin McCloskey, what they think about this roster and the long road ahead. (And perhaps a bit about the big tournament this summer!) Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Good evening Vital family and friends. We are so blessed to have you join with us this evening as we begin our series on “Working At God's Altar”, following the book of the same title written by Don Nordin. If you are joining us on any of our social media platforms, we invite you to download our Vital Church app from the Apple App Store or Google Play Store so you can access the work sheet to follow along with the lesson.New to Vital Church? Connect with us here! https://myvital.church/new-here•Need Prayer? We would love to pray for you! https://myvital.church/prayer-request•Made a decision for Christ? https://myvital.church/made-a-decision•Looking to give? https://myvital.church/give 

The TKI Crew returns for Winter 2026! On Today's episode, Jill ,Tori and Kira discuss how college goalkeepers can transition into coaching. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's that time of year again as the Geek Salad crew waxes nostalgic about the music from 30 years ago. In this installment, they discuss the singles of the year 1996! And stay tuned for Side 2: The Albums next week! Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

The Bible clearly indicates that the variety of ministries and giftings are not to fragment the church, but always to unite the church. Functioning in those gifts to help each other grow in maturity in Christ, with the singular goal of being like Jesus.--To hear more messages from The Image Church, subscribe to our podcast or YouTube channel. Also follow us on social media (Facebook and Instagram) or download our Image Church app in the App Store and Google Play Store to learn more about us and stay up to date.

Headlines:-  Australians' biometric info will be given to United States agencies such as ICE and the Trump administration, by the Albanese government.-  New figures show that the number of people in Australia living with dementia is growing. Iand is expected to more than double to reach over million by 2065.-  National Housing Campaign Everybody's Home has found that frontline services are currently being pushed to a breaking point due to the worsening of the housing crisis.-  On the 9th of February across Australian cities, masses protested against Israeli President Isaac Herzog's Australia visit. 7:15am://Maree Pardy is the lead author of a new report by Footscray Community Response, which evaluates Maribyrnong Council's use of security patrols to address social and health issues. Maree spoke to Jennifer Borrell for 3CR's Think Again about this report and the controversial security program that has been found to make the area less safe. This February (2026), Maribyrnong Council will vote on whether Footscray's unhoused community and other “undesirables” using public space should continue to be surveilled and criminalised by private security guards. Join FCR at 5:45pm on Tuesday 17 February at Maribyrnong Town Hall for a speak-out. You can find out more by going to footscraycommunity.net or follow @footscraycommunity on Instagram. To catch the full conversation head to https://www.3cr.org.au/thinkagain   7:30am://On last week's show, we spoke to Lucinda Thorpe, Online Privacy campaigner at Digital Rights Watch, about the tech giant Palantir, it's influence of US and world politics as well as its roles in enabling the Israel's genocide of Palestinians and ICE in the US. Lucinda joins us again this morning for Part 2 of this discussion, where she will be speaking to us about Palantir's Australian clients, both governmental bodies and corporations.  You can read more about Palantir by going to digitalrightswatch.org. Cam Wilson, reporter at Crikey, has also written about the tech company's ties to Australia. Go to crikey.com.au to find the article. 7:45am://Mai Saif is a Palestinian organiser with Free Palestine Melbourne. In this speech from the protest against Isaac Herzog held at Flinders St Station on Monday, 9th of February, Mai shared her lived experience of living through Israel's brutality as a child, and how the settler occupation dehumanises Palestinians as part of their ideology. Whilst confronting and horrific, Mai ends on the inspiring words of her grandfather, who nurtured in her a spirit of resistance and steadfastness, or sumud. A snap rally has been called for this Thursday, 3 pm at Southern Cross Station, when Isaac Herzog will be in Melbourne. 8:05am:// Renee Chopping is a Campaigns Strategist at Collective Shout and a trauma counsellor. Collective Shout is a grassroots campaign against the sexual objectification of women and girls in media, advertising and popular culture. Renee is here today to talk about Collective Shout's campaign pushing for the App Store and Google Play Store to remove the Grok app after its image editing app has been used to undress women and children. For more info go to https://www.collectiveshout.org/ Or collective.shout  8:20:// Janice Gobey is the chair for writers Victoria and is here to discuss the decision for Creative Victoria to abruptly cut 100 per cent of annual funding provided to the Victorian writers organisation. Writers Victoria is a Melbourne based centre that provides assistance to writers, providing them with work opportunities, mentorship and has assisted many Melbourne based writers in the production of their work; from novels to screenplays. You can sign the petition to help prevent Creative Victoria's decision at https://www.parliament.vic.gov.au/get-involved/petitions/restore-funding-for-writers-victoria/ Songs:- Rabina Mana - Ajak Kwai - Folk Bitch Trio - The Actor - (not a love song)

FC Cincinnati has officially played ten years of soccer for the Queen City. Fans have experienced a decade of the highest highs and lowest lows, and we here at Cincinnati Soccer Talk have been there every minute along the way. We've held wooden spoons and supporter shields with the fans. We've held the microphones in front of the players and coaches. Ever since the hosts met for their first podcast in February of 2016, CST has worked to paint the picture of Cincinnati as a soccer city. (In some cases, that paint involved actual body paint!) To open the year's first Jersey Swap podcast, we've brought in some of our alumni—Nick Seuberling, Bryan Weigel, and Bill Wolf—to talk about CST's origins and best moments. Additionally, we ask them about how confident we feel about the 2026 season. And maybe we wrap things up with a quiz to see how well the triad remember that first season! Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Every other week I'm republishing one of my most popular or impactful episodes from my backlog of over 450 episodes. This week I'm highlighting Episode 410, which is all about post-op pediatric airway emergencies.  You don't want to miss this one! ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠Episode 140⁠ - Listen to episode 140 for an overview of pediatric respiratory distress. ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠Study Sesh⁠ - Change the way you study with this private podcast that includes dynamic audio formats including podquizzes, case studies and drills that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh!  ⁠Straight A Nursing App⁠ - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store. NCLEX Study Plan - Not sure how to plan your NCLEX studying or which topics to focus on? Grab this free guide which details strategies based on how much time you have to prepare.

This week, Marianna sits down with Chris Bositis and Cara McAnaney from the National Clinician Consultation Center (NCCC) to talk all about lower-barrier substance use and HIV prevention and treatment. Tune in to learn how direct-to-inject ties into that and why it matters for you as an HIV care provider. -- Resources: Waters RC, Hoog J, Bell C, Toland P, Valley J, Hurtado L, Kallsen MA, Johnson T, Gerard A, Fockele CE, Klein JW. Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting. JAMA Netw Open. 2025 Aug 1;8(8):e2527016. doi: 10.1001/jamanetworkopen.2025.27016. PMID: 40815514; PMCID: PMC12357186.Rosenwohl-Mack S, Suen LW, Logan AA, Peterson D, Snyder HR. Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series. Subst Use Addctn J. 2025 Oct;46(4):1064-1069. doi: 10.1177/29767342251330412. Epub 2025 Apr 4. PMID: 40183345; PMCID: PMC12353995.D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, Fiellin DA. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702. PMID: 38976265; PMCID: PMC11231806. Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

The TKI Crew returns for Winter 2026! On Today's episode, Jill & Tori are joined by a special guest (possibly a new cast member? :P ) Kira Ketelhut to discuss what are 3 main takeaways from offseason Pro GK training week that young goalkeepers can learn from. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

The fellas are back and in grand fashion covering everything with the week between the NFL in mind: coaching hires, big moves, previewing the offseason and where do the losers of the conference championship go from here?

In this episode of The EV Musings Podcast, Gary discusses the impact of cold weather on electric vehicles, focusing on battery performance, heating solutions, and practical tips for driving in winter conditions.He explains how cold temperatures affect battery chemistry, leading to reduced range, and offers insights into efficient heating methods, including the use of heat pumps and heated accessories.The episode concludes with essential tips for maximising EV performance in cold weather.The EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence.Links in the show notes:Range test: How far can electric cars go in winter?Episode produced by Arran Sheppard at Urban Podcasts: https://www.urbanpodcasts.co.uk(C) 2019-2026 Gary ComerfordSupport me: Patreon Link: http://www.patreon.com/evmusingsKo-fi Link: http://www.ko-fi.com/evmusingsThe Books:'So, you've gone electric?' on Amazon : https://www.amazon.co.uk/dp/B07Q5JVF1X'So, you've gone renewable?' on Amazon : https://amzn.to/3LXvIckSocial Media:EVMusings: Twitter https://twitter.com/MusingsEvInstagram: @EVmusingsOctopus Energy referral code (Click this link to get started) https://share.octopus.energy/neat-star-460Upgrade to smarter EV driving with a free week's trial of Zapmap Premium, find out more here https://evmusings.com/zapmap-premiumMentioned in this episode:ZapmapThe EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence. Zapmap is free to download and use, with subscription plans for enhanced features such as using Zapmap in-car on CarPlay or Android Auto, and discounted charging across thousands of charge points. Download the app from the Apple App Store or Google Play Store or find out more at www.zapmap.com.Zapmap EV GuideGlobal Women in EV DayThis episode is supported by Global Women in EV Day, an international movement founded by Gill Nowell to celebrate and accelerate the women driving the EV transition. Launching globally on 10 February 2026, the campaign brings the sector together around visibility, equity and action. More info: gillnowell@hostedbygill.co.ukGlobal Women in EV Day

We've all made New Year's resolutions before, right? Right? Okay, not all of us. But at least 3 out of 4 Geek Salad members at least remember making a resolution at some point in the past. So to chat about some of those and just kick off the new year in general, they give you episode 263: Resolve to Resolve My New Year's Resolutions. Join Andy, Mike, Joe, and Katherine as they talk about New Years past, present, or yet to come. How many resolutions have they made and kept versus made and completely forgot about a week later? And what do they have planned for the upcoming 12 months? Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.

Bill Reno is back with a new season of  "Gloves Off" where he takes an unfiltered look at the game with candid conversations w/ former GK's.  This week Bill is joined by Dynasty GK Founder & Former USWNT WC Winning GK Tracy Noonan. The Two discuss her college career, the state of USWNT, and how she's paying it forward to the next generation with Dynasty GK.   Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 More Info on All our shows at www.theuniongk.com *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

When overhead is high, you buy cheaper supplies. But there's a better way! In this episode, Kirk Behrendt brings back Ariel Siegel, one of ACT's amazing coaches, to continue the series on overhead and break down supplies percentage. She shares why your numbers may be high, how that impacts your practice, and what you can do about it. For the treatment plan to reduce waste and overspending on supplies, listen to Episode 1000 of The Best Practices Show!Learn More About Ariel:Send Ariel an email: ariel@actdental.com Follow Ariel on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:...

We had a kwentuhan with G Delivers last Philippine Startup Week 2025!G Delivers is your All-in-One Delivery & Transport App! Get food, pharmacy items, groceries, shop essentials, parcels, e-commerce orders, all in one app. Download now on Google Play Store! About to launch in App Store!This episode is recorded live at the Philippine Innovation Hub in Marikina City.In this episode:00:00 Introduction02:33 Ano ang G Delivers?How can listeners find more information?G DELIVERSWebsite: https://g-delivers.comFacebook: https://facebook.com/gdeliversphilippinesPHILIPPINE STARTUP WEEKWebsite: https://phstartupweek.comFacebook: https://facebook.com/PhilippineStartupWeekTHIS EPISODE IS CO-PRODUCED BY:Kredit Hero: ⁠⁠⁠https://kredithero.com/⁠⁠⁠Yspaces: ⁠⁠⁠https://knowyourspaceph.com⁠⁠⁠Twala: ⁠⁠⁠https://twala.io⁠⁠⁠Symph: ⁠⁠⁠https://symph.co⁠⁠⁠Secuna: ⁠⁠⁠https://secuna.io⁠⁠⁠SkoolTek by Edfolio: ⁠⁠⁠https://skooltek.co⁠⁠⁠MaroonStudios: ⁠⁠⁠https://maroonstudios.com⁠⁠⁠CompareLoans: ⁠⁠⁠http://compareloans.ph⁠⁠⁠CHECK OUT OUR PARTNERS:Ask Lex PH Academy: ⁠⁠⁠https://asklexph.com⁠⁠⁠ (5% discount on e-learning courses! Code: ALPHAXSUP)ArkoTech: ⁠⁠⁠https://www.arkotechspacesolutions.com/⁠⁠⁠DVCode Technologies Inc: ⁠⁠⁠https://dvcode.tech⁠⁠⁠NutriCoach: ⁠⁠⁠https://nutricoach.com⁠⁠⁠Argum AI: ⁠⁠⁠http://argum.ai⁠⁠⁠PIXEL by Eplayment: ⁠⁠⁠https://pixel.eplayment.co/auth/sign-up?r=PIXELXSUP1⁠⁠⁠ (Sign up using Code: PIXELXSUP1)School of Profits: ⁠⁠⁠https://schoolofprofits.academy⁠⁠⁠Founders Launchpad: ⁠⁠⁠https://founderslaunchpad.vc⁠⁠⁠Hier Business Solutions: ⁠⁠⁠https://hierpayroll.com⁠⁠⁠Agile Data Solutions (Hustle PH): ⁠⁠⁠https://agiledatasolutions.tech⁠⁠⁠Smile Checks: ⁠⁠⁠https://getsmilechecks.com⁠⁠⁠CloudCFO: ⁠⁠⁠https://cloudcfo.ph⁠⁠⁠ (Free financial assessment, process onboarding, and 6-month QuickBooks subscription! Mention: Start Up Podcast PH)Cloverly: ⁠⁠⁠https://cloverly.tech⁠⁠⁠BuddyBetes: ⁠⁠⁠https://buddybetes.com⁠⁠⁠HKB Digital Services: ⁠⁠⁠https://contakt-ph.com⁠⁠⁠ (10% discount on RFID Business Cards! Code: CONTAKTXSUP)Hyperstacks: ⁠⁠⁠https://hyperstacksinc.com⁠⁠⁠OneCFO: ⁠⁠⁠https://onecfoph.co⁠⁠⁠ (10% discount on CFO services! Code: ONECFOXSUP)Wunderbrand: ⁠⁠⁠https://wunderbrand.com⁠⁠⁠Uplift Code Camp: ⁠⁠⁠https://upliftcodecamp.com⁠⁠⁠ (5% discount on bootcamps and courses! Code: UPLIFTSTARTUPPH)START UP PODCAST PHYouTube: ⁠⁠⁠https://youtube.com/startuppodcastph⁠⁠⁠Spotify: ⁠⁠⁠https://open.spotify.com/show/6BObuPvMfoZzdlJeb1XXVa⁠⁠⁠Apple Podcasts: ⁠⁠⁠https://podcasts.apple.com/us/podcast/start-up-podcast/id1576462394⁠⁠⁠Facebook: ⁠⁠⁠https://facebook.com/startuppodcastph⁠⁠⁠Patreon: ⁠⁠⁠https://patreon.com/StartUpPodcastPH⁠⁠⁠PIXEL: ⁠⁠⁠https://pixel.eplayment.co/dl/startuppodcastph⁠⁠⁠Website: ⁠⁠⁠https://phstartup.online⁠⁠⁠This episode is edited by the team at: ⁠⁠⁠https://tasharivera.com⁠⁠

Success isn't just about the medals. In this episode, Kirk Behrendt brings back Dr. Amanda Seay, president of the AACD, and Dr. Zach Sisler, board chair of the AACD, to share their journeys and lessons of the accreditation process and the importance of investing in yourself for your future. To learn what success could look like for you, listen to Episode 999 of The Best Practices Show!Learn More About Dr. Seay & Dr. Sisler:Join Dr. Seay on Facebook: https://www.facebook.com/DrAmandaSeayFollow Dr. Seay on Instagram: https://www.instagram.com/dramandaseayJoin Dr. Sisler on Facebook: https://www.facebook.com/SmilesBySislerFollow Dr. Sisler on Instagram: https://www.instagram.com/dr_zachsislerRegister for the AACD Scientific Session (April 16-18, 2026): https://www.aacdconference.com/event/1a1b9fe4-2097-4006-b107-822d4da3654b/main-menuMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store:

This week, Marianna sits down with John Faragon to talk about managing missed doses of common injectable medications for treating HIV. Learn all about the different medication options and paths to take as an HIV care provider when doses have been missed. --Long-Acting Injectable PrEP: https://nastad.org/sites/default/files/2023-04/LAI-FAQ-Formatted-Updated4.17.23.pdfLenacapavir as HIV PrEP: https://www.cdc.gov/mmwr/volumes/74/wr/pdfs/mm7435-H.pdf--Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

Your expenses go up year over year — and so should your fees! In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to help you think better about your fees and provide tips for when and how to raise them. To learn how to start owning your value and charging what you're worth, listen to Episode 998 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email to learn more about ACT: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

I18 GK Podcast is proud to present a very special conversation with US Soccer's Head of Goalkeeping Jack Robinson.  The crew chat how to develop a nat gk program, how to build a goalkeeper pool in a country of such scale, and how US Soccer is paving the way for cultural gk exchange from grassroots all the way to the professional game!  Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code:  Union GK members can save an additional 10% with code:  UGK23.  Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment.  Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients treated with ADT alone, ADT and an ARPI, ADT and docetaxel, and ADT, an ARPI, and docetaxel whose disease has progressed to mCRPC and the evidence that underpins these changes. Dr. Taplin highlights the updated algorithms within the guideline and the living format which will provide rapid, up-to-date, evidence-based information for clinicians and patients. Read the full living guideline update, "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." at www.asco.org/genitourinary-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02693 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Mary-Ellen Taplin from Dana-Farber Cancer Institute, lead author on "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." Thank you for being here today, Dr. Taplin. Dr. Mary-Ellen Taplin: Thank you, Brittany. It is a pleasure. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Taplin who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To dive into the content here and what we are here today to talk about, this living clinical practice guideline for systemic therapy for patients with metastatic castration-resistant prostate cancer is updated on an ongoing basis. Dr. Taplin, what prompted this latest update to the recommendations? Dr. Mary-Ellen Taplin: Thank you, Brittany. Several things prompted the latest update. There have been several phase III trials that have been practice-changing that have resulted in the last several years that needed to be added to the guidelines to inform clinicians of comprehensive treatment options. Brittany Harvey: Great, and it is great to have this updated guideline for readers. I would like to review the changes to the recommendations in this latest iteration across the patient populations that are outlined in the guideline. So, starting with: What are the updated recommendations for patients previously treated with androgen deprivation therapy alone whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: A nice feature of this guideline is that in addition to the tables, which provide detailed options, is at the end of the guidelines, our readers will find very clear algorithms that describe past treatment scenarios that patients could have had and then outline their treatment options. So it is very clear. Our clinicians will love these algorithms. And one of the changes for the disease state that you mentioned, which is the least treated castration-resistant state of prostate cancer which is previously treated with ADT alone, is that we recommend testing for mutations in the HRR, homologous recombination repair, genes. And the ones that are specifically known and applicable to prostate cancer are the BRCA genes. So there is clear recommendation of testing to remind us, as treating physicians, that now is the time, if it hasn't been done before, to institute both germline and somatic testing. And somatic testing, if it can be done on tissue, is preferable, but if not, the liquid biopsy approaches, the ctDNA approaches, have now advanced to the point that most patients with metastatic prostate cancer will be able to successfully have testing on the liquid biopsies. So that is number one, testing. And then the new treatment options include, if a patient does have an HRR gene alteration, and maybe about 20-25 percent of patients will be in that category, the combinations of an androgen pathway inhibitor and a PARP inhibitor are now treatment options. So for instance, talazoparib and enzalutamide; olaparib and abiraterone; or niraparib and abiraterone are some of the newer treatment options if the patient is HRR-positive. So, Brittany, in regard to patients treated with ADT alone, another new treatment option is the combination of radium-223 with enzalutamide. This is data based on the PEACE-3 trial which did show both an rPFS and OS benefit. For the patient who is HRR-negative and has previously not had an ARPI, just ADT alone, the combination of radium and enzalutamide is a new recommendation added to the algorithm. Brittany Harvey: Great. Thank you for reviewing those options for that patient population. And as you mentioned, I think those algorithms are very helpful as figures in the document. They are clear and can be used as at-a-glance tools for clinicians in their busy clinics. So then the next patient population that the guideline addresses: What is new for patients previously treated with androgen deprivation therapy and an androgen receptor pathway inhibitor whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Right, so there are several new treatment options. So one is lutetium-PSMA-617, the trade name of which is Pluvicto. So that has now been FDA approved to use after progression on an AR pathway inhibitor and prior to the use of docetaxel chemotherapy. Brittany Harvey: Thank you for reviewing that new option for patients treated with androgen deprivation therapy and an ARPI whose disease has progressed. So then moving into the next set of recommendations, what does the panel now recommend for patients previously treated with androgen deprivation therapy and docetaxel whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: The next group of patients is those treated with ADT and docetaxel but haven't had an AR pathway inhibitor. Treatment options, again the HRR testing is important. So all patients with metastatic castration-resistant prostate cancer should be considered for both germline and somatic testing. I will repeat that. And if they are BRCA mutation positive, then the option of talazoparib and enzalutamide; olaparib and abiraterone; and niraparib and abiraterone.  So the AR pathway inhibitors plus the PARPs. There are three choices, so that can be somewhat complicated to think through, but most practitioners will get familiar with one of those combinations and be their go-to. So those are for BRCA-positive or HRR-positive. The talazoparib/enzalutamide trial also included non-BRCA HRR-positive gene mutations. And if they are HRR-negative, the option that we discussed above of radium and enzalutamide is new to the guideline. Brittany Harvey: Great. And then the last category of patients that is addressed in this update: What has changed for patients previously treated with androgen deprivation therapy, an androgen receptor pathway inhibitor, and docetaxel whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Well, in this space, patients who are heavily pretreated with ADT and ARPI, one or even two, and chemotherapy, generally with docetaxel, the recommendations are not new within the last year or two. And they include Pluvicto; a PARP inhibitor if HRR-positive and they have not had one; second-line chemotherapy such as cabazitaxel. And if they are a very rare group and they have been sequenced and they are MSI-high, then considering a PD-1 inhibitor such as pembrolizumab can be considered. I will note that this is a very small percentage of mCRPC patients, probably in the order of 5 percent or less. Brittany Harvey: Understood. And I appreciate you reviewing the recommendations across all of these patient populations. It sounds like some of the key points is that HRR testing is very important for this patient population, and that the algorithms and the tables in the manuscript provide the full list of options that clinicians and patients can refer to. Dr. Mary-Ellen Taplin: Those are the highlights. And I will note in the tables, all the sections have "Special Considerations" sections because patients never fall into the black and white of one category. And those practical information or special situations sections of each of the recommendations can also help clinicians think about the individual patient in front of them and how they might choose one therapy over another since there are generally choices in all of these treatment situations. Brittany Harvey: Absolutely. That information for the individualized patient-clinician decision-making is really key when, as you said, there is a list of options to choose from. So in your view, what should clinicians know as they implement this living guideline update, and how do these changes impact patients? Dr. Mary-Ellen Taplin: I am so excited about this living document. ASCO has invested to developing the software to, in real time and iteratively, assess the new data that is published in prostate cancer and other diseases. So now we don't have to wait many years for the next guideline to come out. The guidelines will be updated every six months in prostate cancer based on this automatic search of the literature and a standing panel of both academic and community experts in prostate cancer treatment. So we no longer have to wait. That is what makes this guideline stand out to other guidelines. And in the digestible format that we have made, a clinician can seek out the table and read some details, seek out practical information for the recommendations, or they can just go right to the clear figure algorithm and take a quick snapshot. "Yep, I need to do HR testing. Done. Oh, okay. HR-positive or negative, these are my options," and then think about the individual patient in front of them when there is more than one option. For instance, a patient with cardiovascular history, abiraterone might not be a good choice for them. Or a patient with neuropathy, docetaxel might not be a good choice for them. But, within this guideline, it really will be up to date and focused on the busy clinician and knowing what the options are for their patient. Brittany Harvey: Definitely. This new era of living guidelines is very exciting and can provide even more up-to-date, evidence-based recommendations to really support clinicians and patients with metastatic castration-resistant prostate cancer. So in that vein, finally, what is the panel examining, and what are you excited for for new data coming out for future updates to this living guideline? Dr. Mary-Ellen Taplin: The future updates will depend on the results of phase III clinical trials. You know, there are many phase III trials ongoing in advanced prostate cancer, some of which include targeted therapy, which has been long awaited in prostate cancer. So such compounds as antibody-drug conjugates that are targeting certain proteins in prostate cancer cells, such as STEAP1, KLK2, B7-H3. So I think we are entering a new era in prostate cancer where we will be targeting cells and delivering drugs and applying them to prostate cancer if the trials are positive. So I think with AI and a large investment in prostate cancer clinical drug development, I think the treatment options for our patients will be rapidly evolving in a manner not previously seen. So the guidelines need to follow along with these developments. Brittany Harvey: Definitely. It sounds like an exciting time for research in metastatic castration-resistant prostate cancer. And we will await the result of those phase III trials to inform this guideline and lead to future updates. So I want to thank you so much for your work to rapidly and continuously update these guidelines and for your time today, Dr. Taplin. Dr. Mary-Ellen Taplin: Oh, it was my pleasure. ASCO has been a leader in this area, and as a practicing clinician, we are thankful for the investment and guidance that ASCO gives us. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

Your accountant says your practice is profitable. So, why doesn't it feel like it? In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down the cash flow gap, what it is, and how not understanding it affects your practice. To learn how to close your cash flow gap so you can grow your practice, listen to Episode 997 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Every year, you set goals to become healthier. But every year, you fall off the wagon! In this episode, Kirk Behrendt brings back Dr. Uche Odiatu, one of ACT's favorite health and wellness gurus, to share three steps to stay on course to improve your health and life. To learn how to stop overthinking and just start doing, listen to Episode 996 of The Best Practices Show!Learn More About Dr. Odiatu:Send Dr. Odiatu an email: odiatudmd@gmail.comFollow Dr. Odiatu on Instagram: https://www.instagram.com/fitspeakersLearn more on Dr. Odiatu's website: http://www.druche.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Things happen that you don't plan for — and you want to be prepared! In this episode, Kirk Behrendt brings back Paul Sletten, founder of The Sletten Group, to share how to plan for the unplanned by creating a crisis coverage group to protect you and your practice. To learn how to plan smarter and have peace of mind, listen to Episode 995 of The Best Practices Show!Learn More About Paul:Give Paul a call: (303) 699-0990Send Paul an email: paul@lifetransitions.com Learn more about The Sletten Group: https://theslettengroup.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Happy New Year! I18 GK Podcast is back for 2026!  99WC Winner Saskia Webber and Comedian Michael Magid are joined by The TKI Podcast and Gloves OFF Crew continue their debate and bracket breakdown of the Final 4 Schools and crown our GKU!   64 Team Bracket avail online .  Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code:  Union GK members can save an additional 10% with code:  UGK23.  Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment.  Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Is your practice creating wealth, or is it just keeping you “busy”? In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down production, why it's important to understand, and how to start improving your numbers. To learn how to be more profitable so you have a better practice and better life, listen to Episode 994 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email to learn more about ACT: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Avoiding conflict is like ignoring a cavity — it will eventually become a crisis! In this episode, Kirk Behrendt brings in Michelle Wakeman, one of ACT's amazing coaches, to share the right way to address conflict so your team and practice can function at their best. To learn how to proactively manage conflict as a leader, listen to Episode 993 of The Best Practices Show!Learn More About Michelle:Send Michelle an email: michelle@actdental.com Follow Michelle on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email to learn more about ACT: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

NECA in the Know kicks off the new year with a conversation about long-acting PrEP. Tune in to hear Marianna's chat with John Faragon about a once-monthly PrEP option. They talk all about advantages, disadvantages, studies, and more. -- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

Are you struggling to figure out shared network agreements? In this episode, Kirk Behrendt brings back Sandi Hudson, founder of Unlock the PPO, to help you navigate the complex world of PPOs with her expert advice. To learn everything you need to know about shared network agreements for the new year, listen to Episode 992 of The Best Practices Show!Learn More About Sandi:Join Sandi on Facebook: https://www.facebook.com/UnlockThePPOFollow Sandi on Instagram: https://www.instagram.com/unlocktheppoLearn more about Unlock the PPO: https://unlocktheppo.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic options across smoldering multiple myeloma, transplant eligible multiple myeloma, transplant ineligible multiple myeloma, and relapsed or refractory multiple myeloma. They highlight the importance of shared decision making and patient-centric care. They comment on the explosion of new treatment options in this space and the impetus for this guideline becoming a living guideline, which will be updated on an ongoing, regular basis. Read the full guideline, "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline" at www.asco.org/hematologic-malignancies-guidelines. TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/hematologic-malignancies-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02587   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Lisa Hicks from St. Michael's Hospital and University of Toronto, and Dr. Joseph Mikhael from the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, co-chairs on "Treatment of Multiple Myeloma: American Society of Clinical Oncology-Ontario Health (Cancer Care Ontario) Living Guideline." Thank you for being here today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: Thanks so much. Dr. Joseph Mikhael: It is a pleasure to be with you, Brittany. Thank you. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Hicks and Dr. Mikhael who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Mikhael, I would like to start by recognizing that this guideline updates the 2019 ASCO-CCO Guideline on the Treatment of Multiple Myeloma. So what prompted this update and what is the scope of this updated guideline? Dr. Joseph Mikhael: It is amazing when we think back in myeloma years, 2019 actually seems a very, very long time ago because really so much has changed in myeloma over these last six to seven years. Indeed, there have been over 150 randomized controlled trials that we didn't have at the prior guideline that we reviewed for this. Myeloma is a disease that has really changed so dramatically over these last several years. Multiple new agents have been introduced. We now have CAR-T cell therapy, bispecific antibodies, and multiple other agents that were not available at the time. Furthermore, with this growing complexity, it is becoming more important than ever to be able to provide practical advice and guidelines to the oncology community. For most oncologists, they have less than 5% of their time dedicated to multiple myeloma. It is important to bring a clarity to them that allows them to care for their patients. And the scope of these guidelines, furthermore, really cover the whole spectrum of myeloma. They go further than our prior guideline where now we have included smoldering multiple myeloma along with frontline therapy and relapsed multiple myeloma. So, we have really tried to provide the full spectrum to our colleagues in oncology to ensure that they have the tools they need to provide the best care possible for their patients. Dr. Lisa Hicks: That is a really terrific summary. And maybe one thing I will just add is it is really unique to have this much literature. I can't think of another guideline that I have ever been involved with that has seen a field move so quickly and develop so many advancements in a period of just over four or five years. Brittany Harvey: Certainly, there is a large volume of evidence that you all had to review for this guideline update. I think to your point probably one of the greater volumes of literature for a guideline update that you both mentioned. Based on that, I would like to review the key recommendations that are updated in this guideline. So Dr. Hicks, that new patient population that Dr. Mikhael mentioned earlier, what are the key recommendations for patients with smoldering multiple myeloma? Dr. Lisa Hicks: So this is the first time that an ASCO guideline is addressing this branch of multiple myeloma care. It is an area where I think some guidance is needed, and smoldering myeloma is not an active cancer. And so one thing that I really want to highlight is that the panel felt very strongly that to recommend any therapy in this space we needed a higher level of evidentiary certainty, of evidentiary confidence, to make recommendations for active therapy. The panel really made two very important recommendations. First of all, the panel did not recommend treatment for low or intermediate risk smoldering myeloma. That is important. And then the area where I think for the first time we have recommended consideration of treatment is patients with high risk smoldering myeloma. And for patients with high risk smoldering myeloma, the panel recommended that it was appropriate to consider either treatment with daratumumab or careful observation. Dr. Joseph Mikhael: And I think that move forward as you have mentioned, Dr. Hicks, is particularly important because it is an area to some degree still of equipoise and many trials are going on in the area. But we do now have a strong phase III trial that supports the use of daratumumab monotherapy for three years when compared to close observation. But of course, that is not for everyone. And one of the key themes of all of our recommendations are going to be now that more and more choices are available, that we have discussions with our patients to ensure that we match the right treatment with the preference of the patient. And I think that is particularly important here in smoldering myeloma. Dr. Lisa Hicks: Multiple myeloma care and the multiple myeloma evidence is really so nuanced, and one of the nuances that readers will appreciate if they read the guideline is that how smoldering myeloma is risk stratified has been different across different trials. And that really adds to the complexity of this recommendation and is one of the reasons that the panel felt that it was appropriate to recommend either observation or treatment. Brittany Harvey: It is great to have these new recommendations for this unique patient population. And as you both mentioned, that individualized patient care is really important across this entire guideline. So then following those recommendations, Dr. Mikhael, what is recommended for initial therapy, autologous stem cell transplantation, post transplant therapy, and measurement of response for patients with transplant eligible multiple myeloma? Dr. Joseph Mikhael: Well, that is an area that has really considerably also grown since the last guideline. Obviously one would have to consult the guidelines to get every last detail, but in essence, we want to assess whether or not patients are transplant eligible or ineligible. And that assessment is not based on age or renal function alone, but indeed on a careful assessment of that patient. When that assessment is made and deemed that a patient is transplant eligible, our recommendation is that a patient typically would receive a quadruplet. That is to say, a monoclonal antibody directed against CD38, a proteasome inhibitor, an immunomodulatory drug, and dexamethasone to be given for approximately four to six cycles followed by the stem cell transplant, followed by potentially another two cycles of consolidation, and then maintenance therapy. A couple of important caveats. One, we do have two different CD38 antibodies that can be used, either daratumumab or isatuximab. Although typically bortezomib is the preferred proteasome inhibitor, consideration can be given to carfilzomib by virtue of the potential toxicity from bortezomib. And then lastly in the maintenance setting, we are typically recommending at least lenalidomide alone, but consideration can be given to dual maintenance therapy as the data is emerging to either add to that daratumumab or carfilzomib. All the while using the IMWG criteria for response. The goal of course is to achieve the deepest response possible and to maintain that response until such time as patients would relapse. Finally, the length of maintenance therapy continues to be an area of equipoise and study in multiple myeloma. And so at minimum, patients would receive two to three years of maintenance therapy, and based on risk status and depth of response it can be considered that patients would potentially come off maintenance therapy, of course always with the caveat that toxicity would influence length of therapy as well. Brittany Harvey: Yes, as you mentioned, evaluating which patients are eligible is extremely important for considering what is recommended in the guideline for both transplant eligible and transplant ineligible patients. So then Dr. Hicks, following those recommendations for transplant eligible multiple myeloma, what are the recommended treatments, goals of therapy, and measurement of response for patients with transplant ineligible multiple myeloma? Dr. Lisa Hicks: You know, I really can't emphasize enough how important an individualized patient assessment is. When we are thinking about the range of patients that are included in this category of transplant ineligible patients, it is a huge range. You may have fairly fit patients in their late 70s all the way to patients in their 90s. And we really want to see that treatments are tailored both to the fitness of the patient, their individual circumstances, and their preferences. And it is a wonderful thing to have lots of options for patients in this circumstance. What the guidelines have recommended for most patients who are transplant ineligible but fit enough for a stronger therapy is quadruplet therapy. So actually therapy that is very similar to what is being recommended in the transplant eligible population but for a longer period of time. And then for those patients who for whatever reason, be it their fitness or their preference, are not appropriate for that quadruplet therapy, the recommendation is for triplet therapy with a combination of lenalidomide, bortezomib, dexamethasone, or very often, more often in most cases, an antibody based approach with an anti-CD38 plus lenalidomide plus dexamethasone. Dr. Joseph Mikhael: The only thing I would add to that, I think we have to also, as we do mention in our recommendations, be particularly cautious with the dosing of these medications. Because even though we think of them as a single agent or a particular class, there can be quite a variation within the dosing regimen that can affect a patient's side effects and their quality of life. And so being very careful with dose modifications, and particularly in the transplant ineligible patient, is an important part of the recommendation as well. Dr. Lisa Hicks: Yeah, this is a podcast so no one can see me nodding vigorously that dose modification is so important particularly with those older and frailer patients, and with particular attention to trying to reduce dexamethasone doses and favoring weekly administration of bortezomib when that drug is used. Brittany Harvey: Absolutely. Considering the risks and benefits and patient preferences is really key to selecting therapy for these patients. So then Dr. Mikhael, for the final overarching patient population addressed in this guideline, for patients with relapsed or refractory multiple myeloma, what treatment options are recommended? Dr. Joseph Mikhael: This of course is, if you will, the biggest part of the guideline because there has been so much done in the relapse setting. And I think we start the guideline by saying a decision has to be made as to when to institute therapy. That there may be some patients with slow biochemical relapse that may be monitored for a period of time. But when the decision is made to initiate treatment, instead of a simple algorithm, the guideline emphasizes the fact that there are multiple choices that can be given to a patient that are going to match what comorbidities the patient has, what they have been treated with before, and of course what their preferences are. I think we highlight two particular areas. That now that CAR-T cell therapy is available as early as first relapse, it should be a consideration by virtue of the fact that it has resulted in such deep and durable responses. But that triplets should also be considered in that earlier relapse setting because we do have multiple classes of agents that can be used. We know that in later relapse options exist including bispecific antibodies for which we have four different choices. And that in general, patients will ultimately receive either a triplet or CAR-T cell therapy in earlier relapse, but there are some patients who may be eligible only for a doublet by virtue of their comorbidities and of their prior therapies. Lastly, it really does emphasize the point as we have mentioned a few times in this podcast, and I am so glad it keeps coming up, is that as I often say we don't treat myeloma, we treat people. And engaging the patient in that conversation to ensure that the right treatment gets matched to the right patients is particularly important because with all the new classes that we have with antibody drug conjugates, with XPO1 inhibitors, the traditional three classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, along with as we have already mentioned CAR-T and bispecific antibodies, it really is an incredible laundry list of choice. And making that choice specific to the patient becomes absolutely critical. I should also lastly note that there are patients who may defer their initial transplant. There may be patients who may be eligible for a second transplant. So autologous stem cell transplant, although primarily used in the frontline setting, may still be a consideration for a smaller subset of patients in the relapse setting. Dr. Lisa Hicks: I think maybe one thing that I would add is an overarching principle which is actually similar to a principle in the first guideline, and that is that in the relapsed or refractory setting, there are many different treatment options. And in fact, the number of treatment options feels like it is evolving every day. But an overarching principle for clinicians to consider is to try and choose combinations of drugs that the patient has either not been exposed to in the past or certainly that they are not refractory to. We really want to be pulling new options out of the toolbox as much as we can. Dr. Joseph Mikhael: Very often we do see where someone may be on a triplet and they are progressing on it and someone just changes out one drug. We have suggested not to take that approach but to take the approach of completely introducing a new therapy when someone is progressing on their current therapy. I think that point is particularly important and the consensus panel was very clear. Brittany Harvey: Understood. That is very helpful when thinking about what options to offer to patients in the relapsed and refractory setting. And as you mentioned earlier, the figures in this guideline provide an outline of options and then the tables really go into some of the details and outcomes of the trials, and those are very helpful for clinicians to refer to. So then Dr. Hicks, we have talked a little bit about some of the nuances of the guideline, but what should clinicians know as they implement these new and updated recommendations? Dr. Lisa Hicks: I think they should feel comfortable that these are trustworthy guidelines. So these are evidence-based guidelines that have been rigorously developed after a very thorough evidence review and put together by a panel of experts who were extremely thoughtful in their review of the evidence. And so all of this contributes to the trustworthiness of the guidance. And then I would also encourage people to take a deep look at the guidelines because of the importance of nuance that is addressed in them, and then to also explore some of the tools that ASCO is developing that helps with implementation including the flow charts that are contained within the guidelines and some additional tools that are available online. Brittany Harvey: Absolutely. The tools and resources for this guideline are available online with the publication and we will provide links to that in the show notes of the episode. So then following that, Dr. Mikhael, how does this guideline update affect patients with multiple myeloma? Dr. Joseph Mikhael: As we sort of intimated earlier, I like to say I don't treat myeloma, I treat people. I think we should always be patient-centric and patient-focused. And I think in the discussion we always were. We always wanted to ensure that multiple factors go into a decision-making process. We are not just looking at the biology of the disease, we are looking at patient factors. Those patient factors include their frailty as we commented in a frailty assessment, their preferences, their comorbidities. And I think, in a day where we have so many choices, we emphasize in the guideline the importance of that conversation with the patient. That, if you will, shared decision-making model where options are laid out and based on the patient factors and the treatment factors they can then be meshed together in the best way so that patients can make the right choice. And of course in conjunction with the guidelines, we have patient friendly summaries of them. And we involved, of course, patients in the development of these guidelines. And I think that is one of the greatest strengths of the ASCO guidelines is that there is a patient with us at the table who is giving their perspective on the guideline as we go forward. So I am very thankful that we have created a product that is, if you will, not only for the providers, the practitioners that are prescribing these agents and that are directly giving the care, but indeed for the very patients who of course have the most at stake here. Dr. Lisa Hicks: Yeah Joe, I am so glad you called out the participation of patient partners in the guideline. It is such an important part and they were really- the patient partner was such an important part of this panel in helping us understand the patient perspective as we developed this guidance. Brittany Harvey: Definitely. It is a hugely important role for the panel and for all of the panel including the patient partners and the experts in the disease to review the evidence and come up with comprehensive recommendations. And yes, as you mentioned, the individualized treatment and the shared decision-making is really paramount to this guideline. Finally, Dr. Hicks, you alluded to earlier the vast number of treatment options that is really exploding in multiple myeloma. And so this guideline is becoming a living guideline continuously updated by ASCO. So what are the outstanding questions regarding this topic and what evidence is the panel looking forward to for future updates? Dr. Lisa Hicks: I am really excited about this. This is one of the first guidelines that will be a living guideline for ASCO and it is such a good fit. You have heard Joe and I say a few times how quickly this field is moving, how complex the field is. I think everyone on the panel knew that no matter how quickly we did it and how deeply we reviewed the evidence, it was inevitable that more evidence would be generated as we were putting out the guideline. In a field like that, it is really important that we find a way to provide evidence-based guidelines quickly to the community. You know, waiting another five years, letting another 150 trials accrue before we do another guideline is not what the community needs. And so ASCO has really risen to this challenge and is committed to living guidelines. And so a living guideline is a guideline that commits to reviewing the evolving evidence on an ongoing basis, watching for practice changing trials, and having a standing panel that will review evidence and update recommendations on a regularly scheduled basis. So that is what a living guideline is, and that is what this guideline is becoming. That is just the first thing in terms of what a living guideline is. And then what are we watching? Well, honestly what aren't we watching? There is so much happening in multiple myeloma. We knew as we put the guideline out that there were trials in process, some trials that had been released at conferences but not yet published. We will be waiting for those and if they are practice changing they will be addressed in upcoming updates. There is new evidence just recently presented around combined anti-CD38 and bispecific antibodies. I don't know yet whether that will be addressed but I wouldn't be surprised if it was. There are so many things coming down the pipeline and it is just wonderful that there is going to be a way to try and address them in a robust fashion. Dr. Joseph Mikhael: Yeah I agree with you, Lisa. I can't think of another disease that would be more relevant for a living guideline. I mean we had difficulty because new data kept coming in as we were making recommendations. And so at some point we had to draw a line and say this is where we will stop and produce this guideline and have it ongoing. And I really look forward to seeing the updates because we know as you mentioned that there are so many things that are on the verge of approval and on the verge of changing the way we manage this terrible disease. And before I close, I would love to remind all of our listeners that as we commented from the start, patient engagement is critical at ASCO and in our guidelines process. Unfortunately we lost a very dear patient during the guidelines process, and that is Jack Aiello. Jack Aiello had been a patient and a patient advocate for many, many years in the myeloma community. And indeed we have actually dedicated these guidelines to his honor. And so I thought it would be valuable for us to mention that today. And we miss you Jack, but we are very grateful that we have been able to dedicate this excellent body of work to your memory. Brittany Harvey: Absolutely. This guideline and your dedication to him is an honor to his memory and we really recognize him in thinking about this guideline. We will look forward to those future trial results that you mentioned, Dr. Hicks, to update this guideline and continue to provide options for patients with multiple myeloma and improve upon those options and shared decision-making with patients. So I want to thank you both for all of your work to develop this guideline and for your time today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: You are so welcome. Thanks for featuring this guideline. Dr. Joseph Mikhael: Thank you so much, Brittany. It has been a privilege. Brittany Harvey: Finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/hematologic-malignancies-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, which is available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Are your lab costs a little too high? In this episode, Kirk Behrendt brings back Robyn Theisen, one of ACT's amazing coaches, to continue the series on overhead and break down lab percentage. They explain what it is, how it impacts your practice, and what to do to maintain a healthy lab percentage. To learn how to lower your lab costs the smart way, listen to Episode 991 of The Best Practices Show!Learn More About Robyn:Send Robyn an email: robyn@actdental.com Follow Robyn on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

On Dec. 10, it was announced that Google would pay nearly $700 million in settlements to people who paid to download apps from the Google Play Store.The announcement came in the form of a statement from multiple state attorneys general, who were collectively suing Google for anti-competitive practices.Google decided to settle this lawsuit—along with several other concessions—and, in so doing, will pay $700 million, the bulk of which will go to the actual users.Let's go through the details of the case: what Google was accused of doing, how the settlement money will be disbursed, and how you can know if you qualify.

We were inundated with new Windows features in 2025, but which ones actually moved the needle? Fortnite isn't just back on iPhone and Android, it's available on Windows 11 on Arm, and it works great! Plus, 2 big mobile wins for Epic Games and some thoughts on the "right" way to roll out AI features.Windows 11 Best Windows 11 updates of 2025, in no particular order... Dark mode improvements to File Explorer Widgets major overhaul with separate widgets and Discovery feed Xbox Full Screen experience - especially good on handhelds, of course, but also any PC you use for gaming with a controller Click to Do (Copilot+ PC only) External fingerprint reader support for Windows Hello ESS -External/USB webcams supported by Windows Studio Effects (Copilot+ PC only) Quick Machine Recovery is the tip of a wave of new foundational features like Admin Protection, Smart App Control (updates), and more that go beyond surface-level look and feel Redesigned Start menu isn't perfect but it's a nice improvement Copilot Vision, though this type of thing may make more sense on phones AI features in Paint, Photos, Notepad, and Snipping Tool Natural language interactions like the agent in Settings, file search, and more (mostly Copilot+ PC only, but you can do this in Copilot as well) Bluetooth LE support for improved audio quality in game chat, voice calls Gaming on Windows 11 on Arm and Snapdragon X: Major steps forward, but the same issue as always Looking ahead to 2026: 26H1, Agentic features that work, potential Windows 12, and AI PCs AI An extensive new interview with Mustafa Suleyman confirms why this guy is special and how confusing it is that Copilot is so disrespected Microsoft Copilot is auto-installing on LG smart TVs and there's no way to remove it GPT-5.2 is OpenAI's answer to Gemini 3 ChatGPT Images is OpenAI's answer to Nano Banana Pro Disney invests $1 billion OpenAI, sues Google Opera Neon is now generally available for $20 per month AI is moving quick as we all know but the bigger issue may be the incessant marketing about features like agents that don't even work now Microsoft is getting pushback on forced Copilot usage, price hikes Google is expanding its use of "experiments" outside of mainstream products with things like NotebookLM, Mixboard, CC, and much more. Maybe this is the better approach: Test separately and then integrate it into existing products Oddly enough, Microsoft does have a Windows AI Lab for this kind of experimentation Many small models vs. one big LLM in the cloud Mobile Fortnite is back in the Google Play Store in the U.S. as Google plays nice Apple loses its contempt appeal, the end of "junk fees" (Apple Tax) is in sight Xbox and gaming Xbox December Update has one big update for the mobile app and one big update for Xbox Wireless Headphones There's a new Xbox Developer Direct coming in January Half-Life 3 may really be happening, but it will be a Steam Machine launch title so it could be a while Tips & picks Tip of the year: De-enshittify Windows 11 App pick of the year: Fortnite RunAs Radio this week: Zero Trust in 2026 with Michele Bustamante Brown liquor pick of the week: Lark Symphony No. 1 These show notes have been truncated due to length. For the full show notes, visit https://twit.tv/shows/windows-weekly/episodes/963 Hosts: Leo Laporte, Paul Thurrott, and Richard Campbell Sponsors: auraframes.com/ink framer.com/design promo code WW outsystems.com/twit cachefly.com/twit